Ayano Fukushima-Nomura

Ayano Fukushima-Nomura

Auto-generated profile, based on publicly available information

Ayano Fukushima-Nomura

Department of Dermatology Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AFAyano Fukushima-Nomura
Ayano Fukushima-Nomura
HKHiroshi Kawasaki
Hiroshi Kawasaki
KYKiyoshi Yashiro
Kiyoshi Yashiro
SOShoko Obata
Shoko Obata
KTKeiji Tanese
Keiji Tanese
MAMasayuki Amagai
Masayuki Amagai
Atopic dermatitis (AD) is a skin disease exhibiting clinical and molecular heterogeneity, thereby jeopardizing the development of personalized treatments. Here we pursue a cross-sectional and longitudinal cohort analysis of 951 whole-skin samples, employing an unsupervised decomposition analysis to link gene expression profiles to disease severity, six distinct skin phenotypes, and blood cytokines representative of given endotypes. Specifically, type 2 and type 17 responses are associated with major skin phenotypes such as erythema and induration, while type 1 response is upregulated in lichen amyloidosis of AD patients. Longitudinal analysis of patients treated with dupilumab finds sustained gene signatures related to type 17 response in lesional skin and upregulated transcription factors in non-lesional skin of patients with poor treatment outcomes. Lastly, several extracellular matrix organization-associated genes are correlated with clinical severity and treatment response to dupilumab. Our findings thus provide potential skin and blood biomarkers for assessing endotypes and therapeutic responses in AD to pave the way for personalized medicine.

2 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAiko Sekita
Aiko Sekita
HKHiroshi Kawasaki
Hiroshi Kawasaki
AFAyano Fukushima-Nomura
Ayano Fukushima-Nomura
KYKiyoshi Yashiro
Kiyoshi Yashiro
KTKeiji Tanese
Keiji Tanese
HKHaruhiko Koseki
Haruhiko Koseki
Atopic dermatitis (AD) is a skin disease that is heterogeneous both in terms of clinical manifestations and molecular profiles. It is increasingly recognized that AD is a systemic rather than a local disease and should be assessed in the context of whole-body pathophysiology. Here we show, via integrated RNA-sequencing of skin tissue and peripheral blood mononuclear cell (PBMC) samples along with clinical data from 115 AD patients and 14 matched healthy controls, that specific clinical presentations associate with matching differential molecular signatures. We establish a regression model based on transcriptome modules identified in weighted gene co-expression network analysis to extract molecular features associated with detailed clinical phenotypes of AD. The two main, qualitatively differential skin manifestations of AD, erythema and papulation are distinguished by differential immunological signatures. We further apply the regression model to a longitudinal dataset of 30 AD patients for personalized monitoring, highlighting patient heterogeneity in disease trajectories. The longitudinal features of blood tests and PBMC transcriptome modules identify three patient clusters which are aligned with clinical severity and reflect treatment history. Our approach thus serves as a framework for effective clinical investigation to gain a holistic view on the pathophysiology of complex human diseases.

23 September 2025 in Allergology International
Verified
Journal Article
Open access
AFAyano Fukushima-Nomura
Ayano Fukushima-Nomura
HKHiroshi Kawasaki
Hiroshi Kawasaki
MAMasayuki Amagai
Masayuki Amagai
Allergic diseases are characterized by heterogeneity driven by complex interactions between genetic, environmental, and immunological factors. Conventional classifications based solely on clinical phenotypes often fails to capture the underlying molecular diversity, thereby limiting therapeutic precision and patient outcomes. Integrative omics-encompassing genomics, transcriptomics, proteomics, metabolomics, and microbiomics-has emerged as a powerful approach to redefine disease mechanisms and advance precision medicine. By integrating high-dimensional molecular data with clinical phenotyping, omics approaches enable the identification of disease endotypes, biomarker discovery, and patient stratification. This review highlights recent developments in clinical-omics integration, with a focus on atopic dermatitis (AD) as a prototypical allergic disease. Drawing from our studies, we illustrate how tissue-level transcriptomic profiling, combined with unbiased computational analysis, can uncover immunological heterogeneity and treatment-response patterns in AD. Additional examples in asthma and food allergy demonstrate how integrated multi-omics can uncover gene-environment interactions and elucidate mechanisms behind disease severity and health disparities. We also address practical and ethical challenges in data harmonization, privacy, and interoperability, and underscore the critical role of computational methods and infrastructure development in enabling clinically meaningful interpretation. Importantly, successful translation of multi-omics data into clinical practice requires iterative, interdisciplinary collaboration between clinicians, data scientists, and basic researchers. By bridging molecular complexity and clinical heterogeneity, integrative omics is reshaping the landscape of allergy research. As technologies evolve, this framework will be crucial for developing predictive models and personalized therapeutic strategies, ultimately bringing us closer to individualized, data-driven care in allergic diseases.

14 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JMJonathan Moody
Jonathan Moody
TKTsukasa Kouno
Tsukasa Kouno
MKMiki Kojima
Miki Kojima
IKIkuko Koya
Ikuko Koya
JLJulio Leon
Julio Leon
CHChung Chau Hon
Chung Chau Hon
Summary: Transcribed cis-regulatory elements (tCREs), such as promoters and enhancers, are fundamental to modulate gene expression and define cell identity. The detailed mapping of tCREs at single-cell resolution is essential for understanding the regulatory mechanisms that govern cellular functions. Prior tCRE catalogs, limited by bulk analysis, have often overlooked cellular heterogeneity. We have constructed a tCRE atlas using single-cell 5’-RNA-seq, capturing over 340,000 single-cells from 23 human tissues and annotating more than 175,000 tCREs, substantially enhancing the scope and granularity of existing cis -regulatory element annotations in the human genome. This atlas unveils patterns of gene regulation, revealing connections between broadly expressed promoters and cell type-specific distal tCREs. Assessing trait heritability at single-cell resolution with a novel tCRE module-based approach, we uncovered the nuanced trait-gene regulatory relationships across a continuum of cell populations, offering insights beyond traditional gene-level and bulk-sample analyses. Our study bridges the gap between gene regulation and trait heritability, underscoring the potential of single-cell analysis to elucidate the genetic foundations of complex traits. These insights set the stage for future research to investigate the impact of genetic variations on diseases at the individual level, advancing the understanding of cellular and molecular basis of trait heritability.

15 January 2024 in Skin Health and Disease
Verified
Journal Article
Open access
PDF file
AFAyano Fukushima-Nomura
Ayano Fukushima-Nomura
STSaeko Takamiyagi
Saeko Takamiyagi
RKRisa Kakuta
Risa Kakuta
YIYoshihiro Ito
Yoshihiro Ito
IHIkuko Hirai
Ikuko Hirai
KTKeiji Tanese
Keiji Tanese
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder affecting the palms and soles. In rare cases, severe patients develop acute extra-palmoplantar lesions often accompanied by arthralgia. Such cases with extensive symptoms often necessitate systemic treatments with variable efficacy and potential side effects. Apremilast, known for its broad immune response modulation, presents promise as a therapeutic option for severe PPP with joint and extra-palmoplantar lesions. This case highlights apremilast as a potential systemic treatment for such cases with minimal side effects.

18 February 2026 in Allergy
Verified
Journal Article
Open access
AFAyano Fukushima‐Nomura
Ayano Fukushima‐Nomura
HKHiroshi Kawasaki
Hiroshi Kawasaki
THTakehiro Hasegawa
Takehiro Hasegawa
EYErika Yanagisawa
Erika Yanagisawa
KTKeiji Tanese
Keiji Tanese
MAMasayuki Amagai
Masayuki Amagai